[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447226":3},{"organization":4,"outcomesModule":7,"designInfo":75,"detailedDescription":74,"studyPopulation":74,"armGroups":81,"interventions":91,"overallOfficials":96,"centralContacts":100,"locations":107,"responsibleParty":293,"collaborators":295,"id":299,"slug":74,"hasResults":300,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":74,"eligibilityCriteria":304,"healthyVolunteers":300,"sex":305,"minAge":306,"maxAge":74,"enrollmentInfo":307,"targetDuration":74,"studyType":310,"phases":311,"briefSummary":313,"conditions":314,"keywords":319,"overallStatus":110,"whyStopped":74,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":330},{"fullName":5,"class":6},"TORL Biotherapeutics, LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":74},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Incidence and severity of adverse events and serious adverse events","Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0","up to 2 years",{"measure":14,"description":15,"timeFrame":16},"Maximum Tolerated Dose (MTD)","Highest administered dose with \\\u003C 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants","28 Days",{"measure":18,"description":19,"timeFrame":12},"Recommended Phase 2 Dose (RP2D)","Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data",[21,24,27,30,33,37,41,44,48,50,53,55,57,60,62,64,66,68,70,72],{"measure":22,"description":23,"timeFrame":12},"Objective Response Rate (ORR)","Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1",{"measure":25,"description":26,"timeFrame":12},"Duration of Response (DOR)","Time from CR or PR to objective disease progression or death to any cause",{"measure":28,"description":29,"timeFrame":12},"Progression Free Survival (PFS)","PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause",{"measure":31,"description":32,"timeFrame":12},"Time to Response (TTR)","Time from start of treatment to complete response or partial response",{"measure":34,"description":35,"timeFrame":36},"1 Year Overall Survival (1YOS)","Proportion of participants alive at 1 year from the start of treatment to death from any cause","1 year",{"measure":38,"description":39,"timeFrame":40},"2 Year Overall Survival (2YOS)","Proportion of participants alive at 2 years from the start of treatment to death from any cause","2 years",{"measure":42,"description":43,"timeFrame":12},"Number of anti-drug antibody (ADA) Positive Participants","Immunogenicity will be measured by the number of participants that are ADA positive.",{"measure":45,"description":46,"timeFrame":47},"Maximum Serum Concentration of TORL-1-23 (Cmax)","PK assessment","21 days",{"measure":49,"description":46,"timeFrame":47},"Minimum Serum Concentration of TORL-1-23 (Cmin)",{"measure":51,"description":46,"timeFrame":52},"Maximum Serum Concentration of TORL-1-23 at Steady State (Cmax,ss)","63 days",{"measure":54,"description":46,"timeFrame":52},"Minimum Serum Concentration of TORL-1-23 at Steady State (Cmin,ss)",{"measure":56,"description":46,"timeFrame":47},"Time of Maximum Serum Concentration of TORL-1-23 (Tmax)",{"measure":58,"description":59,"timeFrame":47},"Time of Minimum Serum Concentration of TORL-1-23 (Tmin)","PK Assessment",{"measure":61,"description":59,"timeFrame":52},"Time of Minimum Serum Concentration of TORL-1-23 at Steady State (Tmin,ss)",{"measure":63,"description":59,"timeFrame":52},"Terminal Half-life (t1\u002F2) of Serum TORL-1-23",{"measure":65,"description":59,"timeFrame":47},"Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23",{"measure":67,"description":59,"timeFrame":52},"Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23",{"measure":69,"description":59,"timeFrame":52},"Apparent volume of distribution during the terminal phase (Vz) of TORL-1-23",{"measure":71,"description":59,"timeFrame":52},"Clearance (CL) of TORL-1-23",{"measure":73,"description":59,"timeFrame":52},"Accumulation ratio (Rac) of TORL-1-23",null,{"allocation":76,"interventionModel":77,"interventionModelDescription":74,"primaryPurpose":78,"observationalModel":74,"timePerspective":74,"maskingInfo":79},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":80,"maskingDescription":74,"whoMasked":74},"NONE",[82,88],{"label":83,"type":84,"description":85,"interventionNames":86},"Monotherapy Dose Finding - Part 1","EXPERIMENTAL","TORL-1-23",[87],"Drug: TORL-1-23",{"label":89,"type":84,"description":85,"interventionNames":90},"Expansion as Monotherapy - Part 2",[87],[92],{"type":93,"name":85,"description":94,"armGroupLabels":95,"otherNames":74},"DRUG","antibody drug conjugate (ADC)",[89,83],[97],{"name":98,"affiliation":5,"role":99},"Nora Ku, MD","STUDY_CHAIR",[101,105],{"name":98,"role":102,"phone":103,"phoneExt":74,"email":104},"CONTACT","310-348-9636","nora.ku@torlbio.com",{"name":106,"role":102,"phone":103,"phoneExt":74,"email":74},"Ibrahim Qazi",[108,125,141,154,169,183,195,208,222,235,250,263,273,283],{"facility":109,"status":110,"city":111,"state":112,"zip":113,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":121,"contacts":122},"Providence Medical Foundation","RECRUITING","Fullerton","California","92835","United States","US",{"type":117,"coordinates":118},"Point",[119,120],-117.92534,33.87029,{"lat":120,"lon":119},[123],{"name":124,"role":102,"phone":74,"phoneExt":74,"email":74},"Yung Lyou, MD",{"facility":126,"status":110,"city":127,"state":112,"zip":128,"country":114,"countryCode":115,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"UCLA - JCCC Clinical Research Unit","Los Angeles","90095",{"type":117,"coordinates":130},[131,132],-118.24368,34.05223,{"lat":132,"lon":131},[135,138],{"name":136,"role":102,"phone":137,"phoneExt":74,"email":74},"Gottfried Konecny, MD","310-794-4955",{"name":139,"role":140,"phone":74,"phoneExt":74,"email":74},"Gottfired Konecny, MD","PRINCIPAL_INVESTIGATOR",{"facility":142,"status":110,"city":143,"state":144,"zip":145,"country":114,"countryCode":115,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"University of Kentucky Medical Center","Lexington","Kentucky","40536",{"type":117,"coordinates":147},[148,149],-84.47772,37.98869,{"lat":149,"lon":148},[152],{"name":153,"role":102,"phone":74,"phoneExt":74,"email":74},"John Villano, MD",{"facility":155,"status":110,"city":156,"state":157,"zip":158,"country":114,"countryCode":115,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":117,"coordinates":160},[161,162],-93.26384,44.97997,{"lat":162,"lon":161},[165,168],{"name":166,"role":102,"phone":167,"phoneExt":74,"email":74},"Boris Winterhoff, MD, PhD","612-624-8003",{"name":166,"role":140,"phone":74,"phoneExt":74,"email":74},{"facility":170,"status":110,"city":171,"state":157,"zip":172,"country":114,"countryCode":115,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Mayo Clinic in Rochester","Rochester","55905",{"type":117,"coordinates":174},[175,176],-92.4699,44.02163,{"lat":176,"lon":175},[179,182],{"name":180,"role":102,"phone":181,"phoneExt":74,"email":74},"Andrea Wahner Hendrickson, MD","855-776-0015",{"name":180,"role":140,"phone":74,"phoneExt":74,"email":74},{"facility":184,"status":110,"city":185,"state":185,"zip":186,"country":114,"countryCode":115,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":117,"coordinates":188},[189,190],-74.00597,40.71427,{"lat":190,"lon":189},[193],{"name":194,"role":102,"phone":74,"phoneExt":74,"email":74},"Emily Slotkin, MD",{"facility":196,"status":110,"city":197,"state":198,"zip":199,"country":114,"countryCode":115,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":117,"coordinates":201},[202,203],-81.69541,41.4995,{"lat":203,"lon":202},[206],{"name":207,"role":102,"phone":74,"phoneExt":74,"email":74},"Alex Adjei, MD",{"facility":209,"status":110,"city":210,"state":211,"zip":212,"country":114,"countryCode":115,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"Sarah Cannon Research Institute Texas Oncology","Tyler","Texas","75702",{"type":117,"coordinates":214},[215,216],-95.30106,32.35126,{"lat":216,"lon":215},[219,221],{"name":220,"role":102,"phone":74,"phoneExt":74,"email":74},"Heather Pulaski, MD",{"name":220,"role":140,"phone":74,"phoneExt":74,"email":74},{"facility":223,"status":110,"city":224,"state":225,"zip":226,"country":114,"countryCode":115,"cosmosGeoPoint":227,"geoPoint":231,"contacts":232},"Virginia Cancer Specialists","Fairfax","Virginia","22031",{"type":117,"coordinates":228},[229,230],-77.30637,38.84622,{"lat":230,"lon":229},[233],{"name":234,"role":102,"phone":74,"phoneExt":74,"email":74},"Alexander Spira, MD",{"facility":236,"status":110,"city":237,"state":238,"zip":239,"country":240,"countryCode":74,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"St. Vincent's Hospital, The Catholic University of Korea","Suwon","Gyeonggi-do","16247","South Korea",{"type":117,"coordinates":242},[243,244],127.00889,37.29111,{"lat":244,"lon":243},[247,249],{"name":248,"role":102,"phone":74,"phoneExt":74,"email":74},"Byoung Yong Shim, MD",{"name":248,"role":140,"phone":74,"phoneExt":74,"email":74},{"facility":251,"status":110,"city":252,"state":74,"zip":253,"country":240,"countryCode":74,"cosmosGeoPoint":254,"geoPoint":258,"contacts":259},"Seoul National University Hospital","Seoul","03080",{"type":117,"coordinates":255},[256,257],126.9784,37.566,{"lat":257,"lon":256},[260,262],{"name":261,"role":102,"phone":74,"phoneExt":74,"email":74},"Bhumsuk Keam, MD",{"name":261,"role":140,"phone":74,"phoneExt":74,"email":74},{"facility":264,"status":110,"city":252,"state":74,"zip":265,"country":240,"countryCode":74,"cosmosGeoPoint":266,"geoPoint":268,"contacts":269},"Severance Hospital","03723",{"type":117,"coordinates":267},[256,257],{"lat":257,"lon":256},[270,272],{"name":271,"role":102,"phone":74,"phoneExt":74,"email":74},"Gun Min Kim, MD",{"name":271,"role":140,"phone":74,"phoneExt":74,"email":74},{"facility":274,"status":110,"city":252,"state":74,"zip":275,"country":240,"countryCode":74,"cosmosGeoPoint":276,"geoPoint":278,"contacts":279},"Asan Medical Center","05505",{"type":117,"coordinates":277},[256,257],{"lat":257,"lon":256},[280,282],{"name":281,"role":102,"phone":74,"phoneExt":74,"email":74},"Shinkyo Yoon, MD",{"name":281,"role":140,"phone":74,"phoneExt":74,"email":74},{"facility":284,"status":110,"city":252,"state":74,"zip":285,"country":240,"countryCode":74,"cosmosGeoPoint":286,"geoPoint":288,"contacts":289},"Samsung Medical Center","06351",{"type":117,"coordinates":287},[256,257],{"lat":257,"lon":256},[290,292],{"name":291,"role":102,"phone":74,"phoneExt":74,"email":74},"Jinseok Ahn, MD",{"name":291,"role":140,"phone":74,"phoneExt":74,"email":74},{"type":294,"investigatorFullName":74,"investigatorTitle":74,"investigatorAffiliation":74,"oldNameTitle":74,"oldOrganization":74},"SPONSOR",[296],{"name":297,"class":298},"Translational Research in Oncology","OTHER","100447226",false,"NCT05103683","First in Human Study of TORL-1-23 in Participants With Advanced Cancer","A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer","Inclusion Criteria:\n\n* Advanced solid tumor\n* Measurable disease, per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Has not recovered \\[recovery is defined as NCI CTCAE, version 5.0, grade ≤1\\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements\n* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23\n* Progressive or symptomatic brain metastases\n* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection\n* History of significant cardiac disease\n* History of myelodysplastic syndrome (MDS) or AML\n* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded\n* If female, is pregnant or breastfeeding","ALL","18 Years",{"count":308,"type":309},90,"ESTIMATED","INTERVENTIONAL",[312],"PHASE1","This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer",[315,316,317,318],"Advanced Solid Tumor","Ovarian Cancer","Endometrial Cancer","NSCLC",[320],"claudin6","2026-02-11",{"date":323,"type":324},"2026-02-13","ACTUAL",{"date":326,"type":324},"2021-11-17",{"date":328,"type":309},"2026-11-15",{"name":5,"class":6},14]